153 related articles for article (PubMed ID: 36475458)
21. A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine.
Fleeman N; Houten R; Chaplin M; Beale S; Boland A; Dundar Y; Greenhalgh J; Duarte R; Shenoy A
BMC Cancer; 2019 Dec; 19(1):1209. PubMed ID: 31830943
[TBL] [Abstract][Full Text] [Related]
22. Prolongation of tumour volume doubling time (midDT) is associated with improvement in disease-specific survival in patients with rapidly progressive radioactive iodine refractory differentiated thyroid cancer selected for molecular targeted therapy.
Sabra MM; Sherman E; Tuttle RM
Clin Endocrinol (Oxf); 2019 Apr; 90(4):617-622. PubMed ID: 30706513
[TBL] [Abstract][Full Text] [Related]
23. Clinical guidance for radioiodine refractory differentiated thyroid cancer.
Gild ML; Topliss DJ; Learoyd D; Parnis F; Tie J; Hughes B; Walsh JP; McLeod DSA; Clifton-Bligh RJ; Robinson BG
Clin Endocrinol (Oxf); 2018 Apr; 88(4):529-537. PubMed ID: 29095527
[TBL] [Abstract][Full Text] [Related]
24. Treatment of Aggressive Thyroid Cancer.
Huang J; Harris EJ; Lorch JH
Surg Pathol Clin; 2019 Dec; 12(4):943-950. PubMed ID: 31672300
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
Brose MS; Nutting CM; Jarzab B; Elisei R; Siena S; Bastholt L; de la Fouchardiere C; Pacini F; Paschke R; Shong YK; Sherman SI; Smit JW; Chung J; Kappeler C; Peña C; Molnár I; Schlumberger MJ;
Lancet; 2014 Jul; 384(9940):319-28. PubMed ID: 24768112
[TBL] [Abstract][Full Text] [Related]
26. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
Brose MS; Cabanillas ME; Cohen EE; Wirth LJ; Riehl T; Yue H; Sherman SI; Sherman EJ
Lancet Oncol; 2016 Sep; 17(9):1272-82. PubMed ID: 27460442
[TBL] [Abstract][Full Text] [Related]
27. Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea.
Song E; Kim M; Kim EY; Kim BH; Shin DY; Kang HC; Ahn BC; Kim WB; Shong YK; Jeon MJ; Lim DJ
Thyroid; 2020 May; 30(5):732-738. PubMed ID: 31910091
[No Abstract] [Full Text] [Related]
28. Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI).
Brose MS; Smit JWA; Lin CC; Tori M; Bowles DW; Worden F; Shen DH; Huang SM; Tsai HJ; Alevizaki M; Peeters RP; Takahashi S; Rumyantsev P; Guan R; Babajanyan S; Ozgurdal K; Sugitani I; Pitoia F; Lamartina L
Thyroid; 2022 Sep; 32(9):1059-1068. PubMed ID: 35950621
[No Abstract] [Full Text] [Related]
29. Multitargeted Kinase Inhibition in Metastatic Differentiated Radioiodine-Refractory Thyroid Cancer: A Look at New Therapeutic Options for a Rare Disease.
Mischler K; Kneifel S; Cathomas R
Oncol Res Treat; 2016; 39(9):548-52. PubMed ID: 27614988
[TBL] [Abstract][Full Text] [Related]
30. Prognosis and prognostic factors of differentiated thyroid carcinoma after the appearance of metastasis refractory to radioactive iodine therapy.
Ito Y; Miyauchi A; Ito M; Yabuta T; Masuoka H; Higashiyama T; Fukushima M; Kobayashi K; Kihara M; Miya A
Endocr J; 2014; 61(8):821-4. PubMed ID: 24871888
[TBL] [Abstract][Full Text] [Related]
31. Clinical Utility of Cabozantinib in the Treatment of Locally Advanced or Metastatic Differentiated Thyroid Carcinoma: Patient Selection and Reported Outcomes.
Roof L; Geiger JL
Cancer Manag Res; 2023; 15():343-350. PubMed ID: 37070083
[TBL] [Abstract][Full Text] [Related]
32. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
[No Abstract] [Full Text] [Related]
33. Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib.
Jafri S; Yaqub A
Cureus; 2021 Aug; 13(8):e17488. PubMed ID: 34595070
[TBL] [Abstract][Full Text] [Related]
34. Evolving approaches in managing radioactive iodine-refractory differentiated thyroid cancer.
Sacks W; Braunstein GD
Endocr Pract; 2014 Mar; 20(3):263-75. PubMed ID: 24126232
[TBL] [Abstract][Full Text] [Related]
35. Radioactive Iodine for Papillary Thyroid Carcinoma.
Chan WWL; Kwong DLW
Methods Mol Biol; 2022; 2534():225-241. PubMed ID: 35670979
[TBL] [Abstract][Full Text] [Related]
36. Radioactive Iodine-Refractory Differentiated Thyroid Cancer in the Elderly.
Gosain R; Alexander JS; Gill A; Perez C
Curr Oncol Rep; 2018 Sep; 20(10):82. PubMed ID: 30206719
[TBL] [Abstract][Full Text] [Related]
37. The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy.
Rivkees SA; Mazzaferri EL; Verburg FA; Reiners C; Luster M; Breuer CK; Dinauer CA; Udelsman R
Endocr Rev; 2011 Dec; 32(6):798-826. PubMed ID: 21880704
[TBL] [Abstract][Full Text] [Related]
38. Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy.
Liu J; Liu Y; Lin Y; Liang J
Endocrinol Metab (Seoul); 2019 Sep; 34(3):215-225. PubMed ID: 31565873
[TBL] [Abstract][Full Text] [Related]
39. A user-friendly nomogram for predicting radioiodine refractory differentiated thyroid cancer.
Meng C; Song J; Long W; Mu Z; Sun Y; Liang J; Lin Y
Front Endocrinol (Lausanne); 2023; 14():1109439. PubMed ID: 36843580
[TBL] [Abstract][Full Text] [Related]
40. Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma.
Crouzeix G; Michels JJ; Sevin E; Aide N; Vaur D; Bardet S;
J Clin Endocrinol Metab; 2012 Sep; 97(9):3046-50. PubMed ID: 22723320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
